Aprea Therapeutics Files 8-K

Ticker: APRE · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1781983

Aprea Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAprea Therapeutics, Inc. (APRE)
Form Type8-K
Filed DateJun 17, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k

Related Tickers: APRE

TL;DR

APRE filed an 8-K, check for updates.

AI Summary

Aprea Therapeutics, Inc. filed an 8-K on June 17, 2024, reporting other events and financial statements. The filing does not contain specific details about the nature of these events or any financial figures within the provided text.

Why It Matters

This filing indicates that Aprea Therapeutics has made a regulatory submission to the SEC, which may contain important updates about the company's operations or financial status.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific material information that would indicate a high-risk event.

Key Players & Entities

  • Aprea Therapeutics, Inc. (company) — Registrant
  • June 17, 2024 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • 3805 Old Easton Road (address) — Principal Executive Offices
  • Doylestown, PA (location) — City, State of Principal Executive Offices
  • 18902 (zip_code) — Zip Code of Principal Executive Offices
  • ( 617 ) 463-9385 (phone_number) — Registrant's telephone number

FAQ

What specific events are being reported in this 8-K filing?

The filing indicates 'Other Events' and 'Financial Statements and Exhibits' as items being reported, but the specific details of these events are not provided in the excerpt.

What is the date of this current report filing?

The date of the report is June 17, 2024.

Where is Aprea Therapeutics, Inc. incorporated?

Aprea Therapeutics, Inc. is incorporated in Delaware.

What is the principal executive office address for Aprea Therapeutics, Inc.?

The principal executive offices are located at 3805 Old Easton Road, Doylestown, PA 18902.

What is the registrant's telephone number?

The registrant's telephone number is (617) 463-9385.

Filing Stats: 476 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-06-17 08:45:18

Key Financial Figures

  • $0.001 — ch registered Common stock, par value $0.001 per share APRE The Nasdaq Stock Mar

Filing Documents

01 Other Events

Item 8.01 Other Events. On June 17, 2024, Aprea Therapeutics, Inc. (the "Company") issued a press release announcing that the first patient was dosed in the ACESOT-1051 Phase 1 trial evaluating oral WEE1 inhibitor APR-1051. A copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference. On June 17, 2024, the Company updated its corporate presentation slide deck. A copy of the corporate presentation slide deck is filed as Exhibit 99.2 hereto and incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press release issued by Aprea Therapeutics, Inc. dated June 17, 2024 99.2 Corporate Presentation (June 2024) 104 Cover Page Interactive Data File (embedded within the inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aprea Therapeutics, Inc. Dated: June 17, 2024 By: /s/ Oren Gilad Name: Oren Gilad, Ph.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.